Results 131 to 140 of about 397,523 (260)

Sickle Cell Leg Ulcer Extending to the Achilles Tendon [PDF]

open access: yesTurk J Haematol, 2023
Asma S, Boğa B, Kaçmaz M.
europepmc   +1 more source

Hong Kong Poison Information Centre: Annual report 2022

open access: yesHong Kong Journal of Emergency Medicine, Volume 33, Issue 5, October 2026.
Abstract Background The Hong Kong Poison Information Centre (HKPIC) has been providing consultation services to healthcare professionals and collecting epidemiological data on poisoning in Hong Kong since 2005. Objective To analyse and report the poisoning data from HKPIC in 2022.
Tin Yat Anthony Chow   +4 more
wiley   +1 more source

An Update on Post‐Surgical Wound Healing Management and Lower‐Cost Alternatives: A Narrative Review for Healthcare Providers

open access: yesHealth Science Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background and Aims Wound care is a critical component of postoperative and chronic disease management, yet rising supply costs, inconsistent insurance coverage, and patient‐level barriers can complicate care in outpatient and home settings.
Joseph D. Quick   +8 more
wiley   +1 more source

A meta-review of the impact of compression therapy on venous leg ulcer healing. [PDF]

open access: yesInt Wound J, 2023
Patton D   +12 more
europepmc   +1 more source

A Novel Sequential Regimen of Efgartigimod and Telitacicept as Fast‐Acting Treatment for Impeding Crisis of MuSK‐MG

open access: yesImmunity, Inflammation and Disease, Volume 14, Issue 10, October 2026.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction. The muscle‐specific kinase (MuSK) antibody‐positive subtype often involves bulbar and respiratory muscles, conferring a high risk of myasthenic crisis. Method We report a very late‐onset MuSK‐MG case complicated by lung infection and acute heart failure,
Tianjiao Duan   +3 more
wiley   +1 more source

Exposure–Response Analyses of Ropeginterferon Alfa‐2b in Essential Thrombocythemia

open access: yesThe Journal of Clinical Pharmacology, Volume 66, Issue 10, October 2026.
Abstract Ropeginterferon alfa‐2b is a new‐generation interferon therapy for the treatment of myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET). This investigation was designed to characterize its population pharmacokinetics–pharmacodynamics (PopPK‐PD) and delineate exposure–response (E‐R) relationships in ET. A population PK
Albert Qin   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy